Thorne Research is putting a recent acquisition in personalized medicine to work, partnering its WellnessFX division with blood diagnostics maker Itamar Medical to market a home test for sleep apnea.
GE and the NFL have named 16 winners in the first stage of its "Head Health Challenge"--a competition that awards each winner $300,000 to further their work in diagnosis and treatment for mild traumatic brain injury. Here are the 16 companies and research efforts that won initial grants in a partnership that proposes to put $50 million into concussion imaging technology.
After more than two years of work on a GLP-1-targeting diabetes drug, partners Boehringer Ingelheim and Zealand Pharma are planning to start over, hitting the brakes on their program and looking to move on with a to-be-determined new compound.
Novartis launched a topical gel in India designed to treat pain associated with osteoarthritis, rheumatism and injury.
Sequenom said the Mayo Clinic's laboratory testing division will start to offer the San Diego company's signature prenatal diagnostic around the world.
Sanofi is joining forces with researchers at Germany's Fraunhofer-Gesellschaft in the hunt for new antibiotics. The pharma giant is setting up a new collaboration that will mingle investigators from both organizations in a team effort to discover novel compounds in the pharma giant's extensive natural product collection.
Biotech billionaire Patrick Soon-Shiong is back to doing cancer drug deals. And he's working with some very familiar partners at Celgene to build up a new platform for nanoparticle albumin-bound drugs--building on the same tumor-targeting tech used for Abraxane.
Johnson & Johnson's innovation center in California will work with a Seattle diagnostics outfit on a biomarker discovery program geared toward spotting patients most likely to respond to targeted therapies.
The Netherlands-based organs-on-chips maker Mimetas and Belgium-based biotech Galapagos have forged a new collaborative agreement to develop such chips--miniaturized 3-D cell culture models that mimic specific aspects of human diseases.
Qiagen and Exosome Diagnostics will partner to develop innovative, noninvasive molecular in vitro diagnostics to detect lung cancer and other malignancies.